Margaret Schot

2.0k total citations
24 papers, 1.5k citations indexed

About

Margaret Schot is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Margaret Schot has authored 24 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 7 papers in Molecular Biology and 4 papers in Cancer Research. Recurrent topics in Margaret Schot's work include Cancer Treatment and Pharmacology (15 papers), Drug Transport and Resistance Mechanisms (5 papers) and Cancer therapeutics and mechanisms (5 papers). Margaret Schot is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Drug Transport and Resistance Mechanisms (5 papers) and Cancer therapeutics and mechanisms (5 papers). Margaret Schot collaborates with scholars based in Netherlands, United Kingdom and Germany. Margaret Schot's co-authors include Jos H. Beijnen, Jan H.M. Schellens, W.W. ten Bokkel Huinink, Hilde Rosing, C.M.F. Kruijtzer, Roxanne C. Jewell, Elaine Paul, Franciska J. Koopman, Marie-Jeanne T. F. D. Vrancken Peeters and Marieke E. Straver and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Surgery.

In The Last Decade

Margaret Schot

24 papers receiving 1.5k citations

Peers

Countries citing papers authored by Margaret Schot

Since Specialization

Citations

This map shows the geographic impact of Margaret Schot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret Schot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret Schot more than expected).

Fields of papers citing papers by Margaret Schot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret Schot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret Schot. The network helps show where Margaret Schot may publish in the future.

Co-authorship network of co-authors of Margaret Schot

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret Schot. A scholar is included among the top collaborators of Margaret Schot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret Schot. Margaret Schot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA18 POSEIDON randomized phase II trial: Tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC) 2021 ·Annals of Oncology ·Mafalda Oliveira, Richard D. Baird, (unknown), (unknown), (unknown), (unknown), Susana Muñoz, (unknown), C. Saura Manich, Mariëtte Schrier, Ingrid A.M. Mandjes, Karolina Sikorska, Margaret Schot, (unknown), (unknown), Karin Beelen, Javier Cortés, Carlos Caldas, Sabine C. Linn	3
2	Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study 2017 ·European Journal of Cancer ·Mette S. van Ramshorst, Erik van Werkhoven, Ingrid A.M. Mandjes, Margaret Schot, Jelle Wesseling, Marie-Jeanne T.F.D. Vrancken Peeters, Jetske M. Meerum Terwogt, Monique E.M.M. Bos, Hendrika M. Oosterkamp, Sjoerd Rodenhuis, Sabine C. Linn, Gabe S. Sonke	18
3	Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients 2014 ·Annals of Surgery ·Mila Donker, Marieke E. Straver, Jelle Wesseling, Claudette E. Loo, Margaret Schot, Caroline A. Drukker, Harm van Tinteren, Gabe S. Sonke, Emiel J. Rutgers, Marie-Jeanne T. F. D. Vrancken Peeters	298
4	Phase II and Pharmacological Study of Oral Docetaxel Plus Cyclosporin A in Anthracycline Pre-Treated Metastatic Breast Cancer 2013 ·Current Clinical Pharmacology ·Helgi H. Helgason, Stijn L.W. Koolen, Erik van Werkhoven, Mirte M. Malingré, C.M.F. Kruijtzer, Alwin D. R. Huitema, Margaret Schot, Wim Smit, (unknown), Jan H.M. Schellens	9
5	Paclitaxel, Carboplatin, and Trastuzumab in a Neo-adjuvant Regimen for HER2-positive Breast Cancer 2013 ·The Breast Journal ·Gabe S. Sonke, Ingrid A.M. Mandjes, M. Holtkamp, Margaret Schot, Erik van Werkhoven, Jelle Wesseling, Marie‐Jeanne Vrancken Peeters, Sjoerd Rodenhuis, Sabine C. Linn	11
6	Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients 2010 ·European Journal of Nuclear Medicine and Molecular Imaging ·Marieke E. Straver, Tjeerd S. Aukema, Renato A. Valdés Olmos, Emiel J. Rutgers, Kenneth G. A. Gilhuijs, Margaret Schot, Wouter V. Vogel, Marie-Jeanne T. F. D. Vrancken Peeters	59
7	Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors 2009 ·Investigational New Drugs ·Roos L. Oostendorp, Petronella O. Witteveen, Brian Schwartz, Liia D. Vainchtein, Margaret Schot, (unknown), Hilde Rosing, Jos H. Beijnen, Emile E. Voest, Jan H.M. Schellens	22
8	Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors 2006 ·Investigational New Drugs ·I. E. L. M. Kuppens, (unknown), Margaret Schot, (unknown), (unknown), Jos H. Beijnen, Emile E. Voest, Jan H.M. Schellens	26
9	Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer 2006 ·British Journal of Cancer ·Helgi H. Helgason, C.M.F. Kruijtzer, Alwin D. R. Huitema, S. Marcus, W.W. ten Bokkel Huinink, Margaret Schot, Jan H. Schornagel, Jos H. Beijnen, Jan H.M. Schellens	32
10	Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer 2003 ·Annals of Oncology ·C.M.F. Kruijtzer, Henk Boot, Jos H. Beijnen, (unknown), Francis Parnis, André Planting, (unknown), R. Williams, Ron A. A. Mathôt, Hilde Rosing, Margaret Schot, Harm van Tinteren, Jan H.M. Schellens	37
11	Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. 2003 ·PubMed ·Mirjam Crul, (unknown), Dick Pluim, Marc Maliepaard, René W.M. Underberg, Margaret Schot, Rolf W. Sparidans, Paul Baas, Jos H. Beijnen, Nico van Zandwijk, Jan H.M. Schellens	7
12	Individual housing during the play period results in changed responses to and consequences of a psychosocial stress situation in rats 2002 ·Developmental Psychobiology ·(unknown), Margaret Schot, Ruud van den Bos, B.M. Spruijt	86
13	Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin 2002 ·Cancer Chemotherapy and Pharmacology ·Jetske M. Meerum Terwogt, Gerard Groenewegen, Dick Pluim, Marc Maliepaard, Matthijs M. Tibben, Albert Huisman, W ten Bokkel Huinink, Margaret Schot, (unknown), Emile E. Voest, Jos H. Beijnen, Jan H.M. Schellens	94
14	An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients 2002 ·Anti-Cancer Drugs ·H.J.G.D. van den Bongard, Dick Pluim, Hilde Rosing, (unknown), Margaret Schot, M. Ravic, Jan H.M. Schellens, Jos H. Beijnen	13
15	Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel 2001 ·Anti-Cancer Drugs ·Jetske M. Meerum Terwogt, W.W. ten Bokkel Huinink, Jan H.M. Schellens, Margaret Schot, Ingrid A.M. Mandjes, Maria Grazia Zurlo, (unknown), Hilde Rosing, Franciska J. Koopman, Jos H. Beijnen	192
16	The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients 2001 ·British Journal of Cancer ·Mirte M. Malingré, J. Schellens, Olaf van Tellingen, Mariët Ouwehand, Heleen A. Bardelmeijer, Hilde Rosing, (unknown), (unknown), Margaret Schot, W.W. ten Bokkel Huinink, (unknown)	55
17	Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours 1999 ·Cancer Chemotherapy and Pharmacology ·Vinodh R. Nannan Panday, Ronald de Wit, Jan H. Schornagel, Margaret Schot, Hilde Rosing, Jan A. Lieverst, W.W. ten Bokkel Huinink, Jan H.M. Schellens, Jos H. Beijnen	6
18	Phase I and Pharmacokinetic Study of a Daily Times 5 Short Intravenous Infusion Schedule of 9-Aminocamptothecin in a Colloidal Dispersion Formulation in Patients With Advanced Solid Tumors 1999 ·Journal of Clinical Oncology ·Virginie M.M. Herben, (unknown), Jan H.M. Schellens, Margaret Schot, Jan A. Lieverst, M. J. X. Hillebrand, (unknown), (unknown), Jos H. Beijnen, W.W. ten Bokkel Huinink	11
19	Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer 1998 ·Anti-Cancer Drugs ·(unknown), W.W. ten Bokkel Huinink, Margaret Schot, I Hudson, Jos H. Beijnen	19
20	Extravasation of topotecan, a report of two cases 1997 ·Journal of Oncology Pharmacy Practice ·(unknown), Laurence J. van Warmerdam, Margaret Schot, R. Dubbelman, W.W. ten Bokkel Huinink, Jos H. Beijnen	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact